Minapharm Pharmaceuticals (MIPH) Net Income
Net Income
EGP 128.22M
Fiscal year 2024
Net income is the profit remaining after all operating costs, interest and taxes are deducted from revenue — the bottom line of the income statement. A negative figure means the company recorded a loss for that fiscal year.
Net income history
| Fiscal year | Net income | YoY growth | Net margin |
|---|---|---|---|
| 2024 | 128.22M | 331.48% | 2.26% |
| 2023 | -55.39M | -109.39% | -1.42% |
| 2022 | 589.91M | 26.48% | 16.29% |
| 2021 | 466.41M | 55.07% | 15.52% |
| 2020 | 300.78M | 113.18% | 12.74% |
| 2019 | 141.09M | 21.21% | 6.88% |
| 2018 | 116.4M | -33.63% | 6.07% |
| 2017 | 175.39M | 432.23% | 10.66% |
| 2016 | 32.95M | -60.28% | 3.18% |
| 2015 | 82.97M | 68.17% | 8.59% |
| 2014 | 49.34M | -39.24% | 5.95% |
| 2013 | 81.2M | 31.71% | 11.4% |
| 2012 | 61.65M | 20.95% | 9.61% |
| 2011 | 50.97M | -34.18% | 8.6% |
| 2010 | 77.44M | 19.04% | 14.52% |
| 2009 | 65.06M | 7.66% | 17.03% |
| 2008 | 60.43M | 46.89% | 17.97% |
| 2007 | 41.14M | -6.78% | 14.94% |
| 2006 | 44.13M | — | 20.65% |
All monetary figures in EGP. Source: Egyptian Exchange via TradingView; annual figures from company disclosures; updated weekly. Prices refresh every 15 minutes during EGX trading hours.